Market Overview

UPDATE: Lake Street Capital Initiates Coverage on BioTelemetry on Good Market Position

Related BEAT
Covance Posts In-line Q1 Earnings; Falls on Trimmed View - Analyst Blog
How BioTelemetry (BEAT) Stock Stands Out in a Strong Industry - Tale of the Tape

In a report published Friday, Lake Street Capital Markets analyst Bruce D. Jackson initiated coverage on BioTelemetry (NASDAQ: BEAT) with a Buy rating and $14.00 price target.

In the report, Lake Street Capital Markets noted, “BioTelemetry is one of the few publicly-traded, pure-play mobile health companies available to investors. Mobile health (which includes telehealth and remote monitoring) is coming into its own as the U.S. healthcare system shifts to an accountable care model where providers are increasingly incentivized to keep patients out of the hospital. One tool being employed in the management of chronic disease is remote monitoring and management, which enables medical practitioners to detect problems and intervene before the patient has to go to the emergency room. The recent acquisition of Cardiocom by Medtronic can be taken as confirmation that mHealth is ready for prime time, and we believe that BioTelemetry is well positioned to take advantage of this trend.”

BioTelemetry closed on Thursday at $8.98.

Posted-In: Bruce D. Jackson Lake Street Capital MarketsAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (BEAT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free